PTPRC and acute myeloid leukemia: To test the therapeutic effect of miR‐125b ASO‐loaded CD33‐targeting RBCEVs in a preclinical model, we sought to establish AML patient‐derived xenograft (PDX) models using CD45+CD33+ peripheral blood cells from an AML patient with a high level of miR‐125b (Figure 7C).